Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SPRUS1140 (026470-0501)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449B/PTO

Complete if Known

Application Number 10/534,193

Filing Date May 6, 2005

First Named Inventor Hill et al.

Group Art Unit

Current State State

				U.S. PATENT DOCUMENTS	;	
Examiner Initials*		U.S. Patent I	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	No.1	Number	Kind Code ² (if known)			

Attorney Docket Number

			FOREIGN PATENT DOCUME	NTS		
Examiner Initials*	Cite No.1	Foreign Patent Docu	ment Name of Patentee or	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			ind Code ⁵ Applicant of Cited Documents (if known)			Т
	A1	WO 95/15338	The University of Queensland	06-08-1995		-

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	A2	CHEN et al., "Isolation, sequence analysis and characterization of a cDNA encoding human chaperonin 10" Biochim. Biophys. Acta, 1219, 189-190 (1994)				
	А3	COOKE et al., "LPS antagonism reduces graft-versus host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation." J. Clin. Invest., 107, 1581-1589 (2001)				
	A4	COOKE et al, "Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idopathic Pneumonia Syndrome: Potential Role for a Gul-Lung Axis of Inflammation." J. Immunol., 165, 6812-6819, (2000)				
	A5	COOKE et al, "An Experimental Model of Idiopathic Pneumonia Syndrome After Bone Marrow Transplantaion: I. The Roles of Minor H Antigens and Endotoxin." Blood, 88, 3230-3239 (1996)				
	A6	DICKSON et al., "Cloning, Expression, and Purification of a Functional Nonacetylated Mammallan Mitochondrial Chaperonin 10." J. Biol. Chem., 269, 26858-864, (1994)				
	A7	ELLIS et al., "Molecular Chaperones." Annu. Rev. Biochem. 60, 321-47, (1991)				

	-
Date	
Considered	
	Considered

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** Unique cristion designation number: "See attached Kinds of U.S. Patent Documents. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)" For Japanese patent documents, the indication of the year of the reging of the Emperor must proceed the serial number of humber of patent document (And of document by the appropriate symbols as indicated on the document under VIPO Standard ST. 16 if possible. "Applicant to place a check mark here! English language."

Butten Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time, you are required to complete this form bould be sent to the Chief Information Office, U.S. Patent and Tindemark Office, P.O. Box 1450, Nexandis, V. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Sox 1450. Alexandis, V. 22313-1450.

Sheet

1

of 3

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number,	Substitute for form	1449B/	PTO	1	Complete if Known		
	INFORMATION DI	SCLO	SURE	Application Number	10/534,193		
	STATEMENT BY A	APPLI	CANT	Filing Date	May 6, 2005		
l				First Named Inventor	Hill et al.		
				Group Art Unit			
	(use as many sheets	as ne	cessary)	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	SPRUS1140 (026470-0501)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	8A	HARTMAN et al., "dentification of a mammalian 10-kDa heat shock protein, a mitochondrial chaperonin 10 homologue essential for asstated folding of trimeric omithine transcarbamoylase <i>in vitro</i> ." Proc. Natl. Acad. Sci. USA, 89, 3394-8, (1992)	
	A9	HILL et al., "Interleukin-11 Promotes T Cell Polarization and Prevents Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation." J. Clin. Invest., 102, 115-123 (1998)	
	A10	HILL et al., "Total Body Irradiation and Acute Graft-Versus-Host disease: The role of Gastrointestinal Damage and Inflammatory Cytokines." Blood, 90, 3204-3213, (1997)	
	A11	HILL et al, "Differential roles of IL-1 and TNF- σ on graft-versus-host disease and graft versus leukemia." J. Clin. Invest., 104, 459-467, (1999)	1-
	A12	KRIJANOVSKI et al, "Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft- Versus-Host Disease," Blood, 94, 825-831, (1999)	
	A13	MORTON et al., "Immunosuppression detected in pregnant mice by rosette inhibition test." Nature, 249; 459-460, (1974)	
-	A14	MORTON et al., "Studies of the Rosette Inhibition Test in Pregnant Mice: Evidence of Immunosuppression?" Proc. R. Soc. Lond., 193; 413-9, (1976)	
	A15	MORTON et al., "Recent Advances in Mammalian Development." Current Topics in Developmental Biology, 23; 73-92 (1987)	

Examiner Signature	Date Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ²For Japanese patent documents, the indication of the pear of the regin of the Emperor must precede the sential number of the patent document. ²Knd of document by the appropriate promoted as indicated on the document under WIPO Standard ST.16 if possible. ²Applicant is to place a check mark here if English language to the applicant of the place a check mark here if English language.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form bound to be sent to the Other Information Office, U.S. Patent and Trademark Office, p.O. Box 1460, Morandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.